What is BIAF's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BIAF?

P/E (TTM) is n/a and 52-week range is $4.56 to $80.70 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BIAF figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BIAF?

The company profile lists revenue (TTM) near $9M, net income (TTM) near $-2.26B, EPS (TTM) near $-6.89 when available from the market-data feed. Figures are informational and may lag live markets.

Where is bioAffinity Technologies Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Antonio, Texas, US, 7.8M shares outstanding, ISIN US09076W3079 when available from company profile and filing metadata.

bioAffinity Technologies Inc

$BIAF

Health Care · Biotechnology

IR Run Scenarios

$4.72

-16.22%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The company is headquartered in San Antonio, Texas and currently employs 57 full-time employees. The company went IPO on 2022-08-26. The company develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.

Employees

Website

bioaffinitytech.com/

IPO

2022-08-26

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)